| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $12.5M | -17.4% |
| SG&A Expense | $5.3M | -10.8% |
| Operating Income | -$17.9M | +3.7% |
| Net Income | -$17.5M | +2.7% |
| EPS (Basic) | -$1.72 | +8.0% |
| EPS (Diluted) | -$1.72 | +8.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $9.9M | -62.6% |
| Current Assets | $11.6M | -60.2% |
| Total Assets | $13.5M | -57.0% |
| Current Liabilities | $2.4M | -25.6% |
| Total Liabilities | $3.9M | -19.3% |
| Stockholders' Equity | $9.5M | -63.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$16.5M | -12.4% |
| Capital Expenditures | $8K | -93.2% |
| Investing Cash Flow | -$8K | +93.2% |
| Financing Cash Flow | $4.0M | +0.0% |
| Free Cash Flow | -$16.5M | -11.6% |